
ePT--the Electronic Newsletter of Pharmaceutical Technology
FDA issues a warning letter to Nephron Pharmaceuticals.


ePT--the Electronic Newsletter of Pharmaceutical Technology
FDA issues a warning letter to Nephron Pharmaceuticals.

ePT--the Electronic Newsletter of Pharmaceutical Technology
SEC Loosens Revenue-Recognition Rules for Vaccine Stockpile Participants

ePT--the Electronic Newsletter of Pharmaceutical Technology
NIAID Boosts Vaccine Innovation but Draws Controversy

The monopoly held by the large pharmaceutical companies within drug discovery could be falling into the hands of biotechnology firms claims Frost and Sullivan.

The survival of Bacillus subtilis spores in dicalcium phosphate, lactose, and corn starch and in their binary mixtures depends on the compressional properties of these materials and on parameters involved during the tableting process, including compression speed.

From politics to paychecks and downsizings to deadlines-what it's like to work for one of the world's largest industries.

If judges and juries lack the scientific knowledge to decide drugsafety cases, how can we protect both companies and patients?

CDER is reorganizing staffs and developing new policies to encourage industry adoption of quality production systems.

Pharmaceutical Technology Europe
Particle shape is an important parameter to monitor in the pharmaceutical sector, but has, historically, been too complicated to measure and be utilized on a routine basis. A newly developed digital technique could change this.

Pharmaceutical Technology Europe
In applying a visually clean standard, any residue related to the cleaning process that is visible on the surface should constitute a failure.

ePT--the Electronic Newsletter of Pharmaceutical Technology
OTC Eye-Drop Maker Signs Consent Decree

ePT--the Electronic Newsletter of Pharmaceutical Technology
Merck to Close Plants, Slash Jobs, Streamline Manufacturing

ePT--the Electronic Newsletter of Pharmaceutical Technology
American Pharmaceutical Partners to Merge with American BioScience

Almost all pharmaceutical manufacturing processes require handling and processing cohesive powders. The application of sufficient shear (i.e., the total deformation that the bulk of granular material undergoes under applied shear stress) is an essential factor in such processes. Sufficient shear is required to mill and de-lump materials, achieve sufficient flow, and homogenize cohesive ingredients. Shear mixing plays a critical role in the blending of dry powders, particularly for those that contain a minor cohesive component such as a solid lubricant or a drug. This mechanism is necessary to achieve a satisfactory homogeneity and disintegrate possible agglomerates. Excessive shear can be disadvantageous, however, and can lead to electrostatic buildup, attrition, and overlubrication.

Solid oral drug products are one of the oldest of all manufactured dosage forms (1). Today, the development of an appropriate formulation of drug and excipients and of an effective manufacturing process to create a tablet or capsule is slowly transforming from a practice of applied art to one of applied science. The US Food and Drug Administration supports this change by expecting sponsors of new drug applications to understand, describe, and control materials and processes as well as the risks associated with drug product manufacturing (2). These steps will ensure the consistent production of products that meet their specifications and remain safe and effective during their shelf life.

The potentially huge demand for vaccines in light of the growing avian flu crisis...

ePT--the Electronic Newsletter of Pharmaceutical Technology
Pfizer to Shut Parsippany Plant

ePT--the Electronic Newsletter of Pharmaceutical Technology
Adjuvant for HPV Vaccine Enhances Immune Response Levels

ePT--the Electronic Newsletter of Pharmaceutical Technology
Chiron Looks to Flu Vaccine Cell Culture; FDA Gears Up

ePT--the Electronic Newsletter of Pharmaceutical Technology
Continuous manufacturing processes?little used in the pharmaceutical industry but the norm in oil, food, chemical, and polymer manufacturing?go hand-in-hand with the current emphasis on quality-by-design and automated process monitoring and control (aka, process analytical technology, PAT).

ePT--the Electronic Newsletter of Pharmaceutical Technology
The process analytical technology (PAT) initiative has been percolating at the US Food and Drug Administration for a long time, explained FDA's John E. Simmons at the AAPS Annual Meeting and Exposition on Wednesday. "If you think of PAT as an isolated set of applications, I think you are missing the point," Simmons said. "The FDA would like PAT to become commonplace?not to be an initiative, but common practice."

ePT--the Electronic Newsletter of Pharmaceutical Technology
This week, the US Food and Drug Administration posted an Oct. 20 Warning Letter (http://www.fda.gov/foi/warning_letters/g5567d.htm) sent by its Minneapolis, MN district office to Diversified Manufacturing Corporation (Newport, MN).

ePT--the Electronic Newsletter of Pharmaceutical Technology
Control Development's (South Bend, IN, www.controldevelopment.com) blend uniformity and dryer monitor consists of a NIR spectrometer, a sampling head, computer, and software.

ePT--the Electronic Newsletter of Pharmaceutical Technology
Generally, tablet and capsule film coatings are applied as aqueous or organic-based polymer solutions or dispersions, graduate student Sagarika Bose (University of Connecticut) explained during her Tuesday AAPS Graduate Student Symposium presentation, "Development and Evaluation of Solventless Photocurable Pharmaceutical Film Coating." However, organic film coatings can be flammable, toxic, and must comply with strict environmental regulations. Aqueous film coating can lead to the degradation of certain drugs by heat and water.

ePT--the Electronic Newsletter of Pharmaceutical Technology
"The better we understand the relationship between process parameters and product attributes, the better control we'll have over product quality," said Beth Fowler, PhD, during Tuesday?s session on process monitoring at the AAPS Annual Meeting.